Nurofen Plus Recalled; Sabotage Suspected - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nurofen Plus Recalled; Sabotage Suspected


ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued several press releases Aug. 25–26, 2011, regarding the discovery of rogue medicines in packs of Reckitt Benckiser’s Nurofen Plus.

The most recent of the press releases announces that Reckitt Benckiser (UK) Ltd is to recall all remaining unexpired stock of Nurofen Plus tablets of any pack size as a precautionary measure. The discovery of AstraZeneca's anti-psychotic drug Seroquel XL in Nurofen Plus packs on Aug. 25, 2011 was followed by a pack containing Pfizer's Neurontin 100mg, used to treat epilepsy, being found in Northern Ireland on Aug. 26, 2011.

The MHRA advised the public in a previous press release to return any packs of Nurofen Plus pain relief tablets to any pharmacy. The release also indicated the differences between the blister packs and medicines contained within. Seroquel tablets are large and capsule shaped in gold and black packaging, Nurofen Plus blister packs are silver and black, and Neurontin tablets are white capsules printed with name of the drug. Ian Holloway from the MHRA's Defective Medicines Report Centre (DMRC) said, "People should check to see if they have any packets of Nurofen Plus. If you do, return them to your nearest pharmacy."

Reckitt Benckiser issued the recall on the Nurofen website and stated, "Sabotage is suspected and we are working with the police on a formal investigation to find the person or persons responsible. Distribution of Nurofen Plus has been halted at this time."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here